As the field of oncology moves from systemic cytotoxic chemotherapies to targeted agents and immunotherapies, the paradigm for dose selection is undergoing a historic shift. For decades, the Maximum Tolerated Dose (MTD) was the "gold standard" for early-phase trials, but today’s clinical trialists and statisticians are increasingly pri...
follow.it gives you an easy way to subscribe to Onbiostatistics's news feed! Click on Follow below and we deliver the updates you want via email, phone or you can read them here on the website on your own news page.
You can also unsubscribe anytime painlessly. You can even combine feeds from Onbiostatistics with other site's feeds!
Title: On Biostatistics and Clinical Trials
